title: Preclinical tolerance and pharmacokinetic assessment of MU-Gold, a novel chemotherapeutic agent, in laboratory dogs.
abstract: MU-Gold, tetrakis (trishydroxymethyl) phosphine gold(I) chloride, a novel gold compound, has cytotoxic effects against human androgen-dependent and -independent prostatic, gastric, and colonic carcinoma in cell culture and against malignant lymphoma in rodent models. A pilot study was conducted to evaluate the tolerance and pharmacokinetic properties of MU-Gold in normal dogs in anticipation of clinical trials in cancer-bearing dogs. MU-Gold (10 mg/kg) was administered by i.v. injection to three purpose-bred dogs. Serum was collected from all dogs for measurement of gold levels via atomic absorption spectrometry. In addition, complete blood counts and biochemical profiles were monitored for Dogs 2 and 3 every 7 days for 30 days. A two-compartment i.v. bolus model with first-order kinetics, mean elimination half-life of approximately 40 hours, and mean volume of distribution of 0.6 L/kg was established. Serum gold concentrations ranging from 10 to 50 mcg/ml were sustained for 2 to 3 days with no clinically significant toxicities observed. Based on in vitro results in earlier studies and preliminary pharmacokinetic data collected in the present study, Phase I clinical trials should be conducted to define the optimal dosage, dose-limiting toxicities, and other characteristics of MU-Gold that will be used to design Phase II clinical trials.
authors.affiliation: Department of Veterinary Medicine and Surgery, University of Missouri-Columbia, Columbia, MO 65211, USA.
authors.forename: Mary Lynn
authors.initials: ML
authors.lastname: Higginbotham
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Henry
authors.forename: Kattesh V
authors.initials: KV
authors.lastname: Katti
authors.forename: Stan W
authors.initials: SW
authors.lastname: Casteel
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Dowling
authors.forename: Nagavarakishore
authors.initials: N
authors.lastname: Pillarsetty
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry / Q000493:pharmacokinetics*; D004285:Dogs; D017612:Gold Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry / Q000493:pharmacokinetics*; D006207:Half-Life; D007275:Injections, Intravenous; D008297:Male; D015394:Molecular Structure; D050607:Organogold Compounds; D009942:Organometallic Compounds; D010720:Phosphines
chemical_list: D000970:Antineoplastic Agents; D017612:Gold Compounds; D050607:Organogold Compounds; D009942:Organometallic Compounds; D010720:Phosphines; C473479:tetrakis((trishydroxymethyl)phosphine)gold(I)